水飞蓟宾胶囊联合^(131)I治疗Graves病合并肝功能损害37例近期疗效观察  

Short-term effect of Silybin in capsule and ^(131)I treatment in Graves patients with liver damage

作　　者：钱江 许泽清[2] 李凤棉 潘立群 胡元元 

机构地区：[1]广东省佛山市顺德区第一人民医院,核医学528300 [2]中山大学第五附属医院

出　　处：《齐齐哈尔医学院学报》2013年第10期1413-1414,共2页Journal of Qiqihar Medical University

摘　　要：目的观察水飞蓟宾胶囊联合131I治疗Graves病合并肝功能损害的疗效及安全性。方法 37例Graves病合并肝损害患者,应用水飞蓟宾胶囊护肝治疗的同时进行131I治疗,观察治疗前、治疗后2周、1月、2月、3月、6月的肝功能变化及治疗后6月的疗效。结果治疗后肝功能与治疗前比较均有显著性统计学差异(P<0.01),治疗2周及1月后肝功能指标较治疗前明显降低,治疗2个月后37例患者中28(75.7%)例肝功能恢复正常,9(75.7%)例患者肝功能指标仍稍高于正常,但较治疗前明显降低,6个月肝功能全部恢复正常。治疗6月后37例Graves病痊愈22例,好转8例,甲低7例,一次治疗痊愈率59.4%,总有效率为100%,甲低发生率18.9%。结论水飞蓟宾胶囊联合131I治疗Graves病合并肝功能损害安全有效,水飞蓟宾能有效改善肝功能,且不影响131I治疗效果。Objective To evaluate the short-term efficacy of Silybin and ^131I treatments in Graves patients with liver damage. Methods A total of 37 Graves patients with liver damage were given Silybin and ^131I therapy, The changes of hepatic functions （ ALT, AST, ALP） ware studied Before treatment, after treatment 2 weeks, 1 month, 2 months, 3 months and 6 months. Results Compared with before treatment, the hepatic functions （ALT, AST, ALP） after treatment 2 weeks, I month, 2 months, 3 months and 6 months were significantly decreased （P 〈 0. 01 ）. After 2 months treatment, 28 （75.7%） patient＇s hepatic functions were normal,9 （75.7%） patient＇s hepatic functions were significantly Improved. 22 （59.4%） patients were cured after 6months, 8 （21.3%） patients were partially remitted, 7 （ 18.9% ） patients showed hypothyroidism; after 6 months treatment, 37 （ 100% ） patient＇s hepatic functions were normal. Conclusions Silybin and m I I treatment is highly effective and safe for Graves patients with liver damage; Silybin can significantly improved the hepatic functions of Graves patients with liver damage.

关 键 词：水飞蓟宾 131I 肝功能损害 GRAVES病 

分 类 号：R581.1[医药卫生—内分泌]